All enrolled individuals who obtained at the least one particular dose of zosuquidar or placebo during induction were monitored with the incidence of adverse functions (439 sufferers, 219 on zosuquidar and 210 on placebo). The most common adverse situations were being linked to the period of extended and considerable myelosuppression https://mannerse443rnb1.ouyawiki.com/user